Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2006

View Archived Issues

Further preclinical data on TC-2216 presented

Promising results seen with CytoFab in phase II sepsis study

Preclinical antidiabetic efficacy of AS100-244, a novel recombinant globular domain of adiponectin

CeNeS updates M6G status

Alagebrium to be studied in cardiovascular aging

ConjuGon awarded SBIR grant for antibiotic-resistant bacterial infection work

Pharmacopeia and Schering-Plough extend research collaboration

Tocosol Camptothecin studied in phase I solid tumor trial

NOV-205 evaluated for hepatitis C in first U.S. study

Supply agreement for AV-299

Positive pharmacokinetic results for NovaDel's sumatriptan oral spray

Memory achieves milestone in PDE10 collaboration with Amgen

Phase I/II trial investigates eniluracil and 5-FU for hepatocellular cancer

Affinium Pharmaceuticals profiles new anti-staphylococcal agent, API-1252

European orphan drug designation recommended for Cytotect

TAP and Novartis to copromote Famvir in U.S.

Novel chloride CIC-7 channel inhibitor PB-5430 reduces bone resorption in OVX rats

Novel GSK-3 inhibitor increases trabecular bone mass in mice

Merck & Co. revises filing plans for MK-0524B

More negative phase III outcomes for Corlux in psychotic major depression

R&D highlights from the UBS Global Life Sciences Conference in New York: Ziopharm Oncology

PF-00422602: Pfizer's novel oxazolidinone active against Gram-positive bacteria

Approvable letter for cryopreserved OrCel in epidermolysis bullosa

Toll-like receptor agonist 3M-003 shows antifungal activity in vitro

Pylera receives approval letter for eradication of H. pylori

NDA submission for EvaMist

Arixtra ACS filing accepted for priority review

European approval for Synvisc in ankle and shoulder osteoarthritis indications

Natural extract from Chinese herb shows benefit in rheumatoid arthritis

E.U. filing for febuxostat in symptomatic hyperuricemia accepted for review

Novel agents for sleep disorders, schizophrenia, etc. claimed in recent patents

Novel therapeutic agents for infectious diseases disclosed in recent patent literature

New therapeutic strategies for cancer imparted in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.